Waterloo Capital L.P. Sells 10,596 Shares of Bristol Myers Squibb Company $BMY

Waterloo Capital L.P. decreased its position in Bristol Myers Squibb Company (NYSE:BMY) by 53.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,106 shares of the biopharmaceutical company’s stock after selling 10,596 shares during the period. Waterloo Capital L.P.’s holdings in Bristol Myers Squibb were worth $411,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of BMY. RMR Wealth Builders increased its position in shares of Bristol Myers Squibb by 11.0% during the third quarter. RMR Wealth Builders now owns 4,808 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 477 shares during the period. Portside Wealth Group LLC increased its holdings in Bristol Myers Squibb by 15.2% in the 3rd quarter. Portside Wealth Group LLC now owns 21,712 shares of the biopharmaceutical company’s stock valued at $979,000 after buying an additional 2,860 shares during the period. HORAN Wealth LLC acquired a new position in shares of Bristol Myers Squibb in the 3rd quarter valued at $454,000. Bessemer Group Inc. lifted its holdings in shares of Bristol Myers Squibb by 7.6% during the 3rd quarter. Bessemer Group Inc. now owns 64,027 shares of the biopharmaceutical company’s stock worth $2,888,000 after acquiring an additional 4,507 shares during the period. Finally, Cullen Capital Management LLC boosted its position in shares of Bristol Myers Squibb by 6.3% during the 3rd quarter. Cullen Capital Management LLC now owns 1,340,847 shares of the biopharmaceutical company’s stock valued at $60,472,000 after acquiring an additional 79,777 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on BMY shares. Guggenheim reissued a “buy” rating and issued a $72.00 price target (up previously from $62.00) on shares of Bristol Myers Squibb in a research report on Friday. Citigroup increased their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their target price for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Piper Sandler reiterated an “overweight” rating and issued a $66.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research report on Wednesday, January 28th. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Eight equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $59.20.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $61.99 on Friday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33. The stock has a market capitalization of $126.20 billion, a PE ratio of 17.97, a PEG ratio of 0.19 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The stock’s fifty day moving average is $54.34 and its 200-day moving average is $49.03.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 70.30%. The business had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the prior year, the firm earned $1.67 earnings per share. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend was Friday, January 2nd. Bristol Myers Squibb’s payout ratio is currently 73.04%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q4 revenue beat and growth portfolio momentum — BMY reported $12.5B in Q4 revenue with growth in new products (immuno‑oncology) helping offset legacy declines; investors view the topline beat as validating the company’s transition. Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
• Positive Sentiment: Upside FY‑2026 guidance — management set FY‑2026 EPS of $6.05–$6.35 and revenue guidance of $46.0–$47.5B, both above consensus, which markets are treating as a material bullish catalyst for forward earnings and cash flow expectations. Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off
• Positive Sentiment: Management and pipeline commentary — CEO Chris Boerner highlighted the strongest pipeline in a decade and called out new growth engines, supporting investor confidence in sustained medium‑term revenue growth. Bristol Myers Squibb CEO: Richest product pipeline we’ve had in the last decade
• Positive Sentiment: Street reaction — Citigroup raised its price target from $60 to $64 (maintaining a neutral rating), signalling modest analyst support for upside after the print and guidance. Tickerreport: Citigroup raises target
• Neutral Sentiment: Dividend/total-return thesis discussed — commentary (Seeking Alpha) frames BMY as a dividend income play with hidden upside from pipeline and buybacks; relevant for income-oriented investors but less immediate as a price catalyst. Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026
• Negative Sentiment: EPS mix and legacy headwinds — non‑GAAP EPS dynamics and year‑over‑year decline in EPS (and some legacy drug declines) remain a risk; some outlets note EPS was below certain Street figures and that company sales may decline in 2026 before new-product gains fully offset legacy erosion. MarketBeat: Earnings and call materials
• Negative Sentiment: Some analysts/publication notes that overall sales could decline in 2026 — this has been flagged as a medium‑term headwind that could pressure consensus if new-product uptake lags expectations. MSN: Bristol Myers expects sales to decline this year

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.